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TNFi treatment, J Infect (2012), httpSummary Objectives: To evaluate the T-cell interferon (IFN)-g response to Mycobacterium
tuberculosis-specific antigens during latent tuberculosis infection (LTBI) therapy in candidates
for tumor necrosis factor-a inhibitors (TNFi).
Methods: 1490 Patients were screened for LTBI. One-hundred and sixty-six of them were
treated for LTBI and followed-up with QuantiFERON-TB Gold (QFT-IT) testing at baseline
(T0) and therapy completion (T1); 92 subjects were also tested 3e6 months after therapy
completion (T2).
Results: At T1 the QFT-IT reversion and conversion rates were 24% (27/111) and 18% (10/55),
respectively. By multivariate analysis, the likelihood of reversion significantly decreased with
older age (>50e60), larger TST size (>15 mm) and higher IFN-g value at T0 (>1 IU/ml); the55 7949479; fax: þ39 055 7949480.
reggi.toscana.it (F. Bartalesi).
ction Association. Published by Elsevier Ltd. All rights reserved.
.10.017
artalesi F, et al., Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for
://dx.doi.org/10.1016/j.jinf.2012.10.017
2 F. Bartalesi et al.Please cite this article in press as: Ba
TNFi treatment, J Infect (2012), httplikelihood of conversion increased with higher IFN-g levels at T0 (1 IU/ml) and in female
patients. Quantitative data among those who scored QFT-IT-positive at T0 showed a decreasing
trend of IFN-g levels between T0 and T1 that reached statistical significance when T0 was
compared to T2, and T1 to T2.
Conclusions: The data confirm the difficulty of interpreting the modulation of IFN-g levels
during LTBI therapy. Currently, there is no evidence to support the use of QFT-IT in the clinical
practice of monitoring LTBI treatment in candidates for TNFi.
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Tumor necrosis factor-a inhibitors (TNFi) have been
approved for treatment of immune-mediated inflammatory
diseases (IMID) and also provide clinical benefits. However,
patients treated with TNFi show an increased risk of serious
life-threatening infections, including reactivation of Myco-
bacterium tuberculosis (MTB) infection.1 Thus, screening
for active tuberculosis (TB) and latent TB infection (LTBI)
has become a mandatory procedure before initiating TNFi
therapy.2e5 In the past decade, several guidelines have
been published on managing LTBI in individuals who are
candidates for treatment with TNFi. However, the recom-
mendations for use and the interpretation of the tuberculin
skin test (TST) and interferon (IFN)-g release assays (IGRAs)
differ among these guidelines. For example, the US Centers
for Disease Control and Prevention recommend performing
either the TST or IGRA before starting any TNFi,6 while the
UK National Institute for Health and Clinical Excellence, for
immunocompromised patients other than HIV-infected
recommend performing an IGRA alone or an IGRAwith a con-
current TST, and scoring positive for LTBI if either test is
positive.7 In our setting, characterized by a low prevalence
of Bacillus CalmetteeGue´rin (BCG)-vaccination, we found
that both TST and QuantiFERON-TB Gold (QFT-IT) (Cellestis
Limited, Carnegie, Australia) are significantly associated
with TB risk factors.8
QFT-IT measures antigen-specific IFN-g secretion by
peripheral blood CD4þ T-lymphocytes, mainly effector T-
cells, in response to in vitro MTB-specific stimulation.9,10
It is hypothesized that the frequency of effector T-cells de-
creases as the mycobacterial antigen load (reflecting bac-
terial load) declines with treatment, and that measuring
T-cell responses to MTB-specific antigens may thus be use-
ful to monitor the treatment.11e18 If this is correct, then
these responses may be used as a tool to monitor the effect
of treatment for LTBI or TB, and as surrogate markers of
cure or predictors of relapse.
Few data are available on the modulation of IFN-g
response during LTBI therapy and most are from studies
carried out on health care workers or close TB con-
tacts.17e25 Only a recent study involves subjects affected
by IMID; however it focused on detecting the impact of
TNFi therapy, rather than of LTBI treatment, on IFN-g levels
by serial IGRA and active TB progression.26
Therefore, the aim of our study was to evaluate the
modulation of T-cell IFN-g response to MTB-specific anti-
gens during LTBI therapy in a large, screened population of
IMID patients in Italy who were candidates for TNFi
therapy.rtalesi F, et al., Serial QuantiFER
://dx.doi.org/10.1016/j.jinf.201Material and methods
Study population
Overall, the conditions of 1490 consecutive IMID patients
were evaluated for LTBI at intervals between May 2006 and
July 2011 in Florence, Italy by a predefined protocol.8 The
subjects were in care at three Florentine outpatient clinics
for rheumatic diseases (rheumatoid arthritis, psoriatic ar-
thritis and ankylosing spondylitis), psoriasis or other immu-
nomediated chronic diseases which required the use of
biological drugs (infliximab, etanercept, adalimumab and
rituximab).27 Informed consent was obtained from each
patient.
Demographic information, data on BCG-vaccination,
treatment regimens in the last 3 months and risk factors
for LTBI were collected during a standardized interview.
Treatments were classified into systemic corticosteroids,
conventional disease-modifying anti-rheumatic drugs
(DMARDs: including methotrexate, azathioprine, cyclospor-
ine, leflunomide, cyclophosphamide and hydroxychloro-
quine), DMARDs mixed with systemic corticosteroids, and
TNFi (infliximab, etanercept, or adalimumab). All subjects
underwent a chest radiograph. Information regarding the
risk factors for LTBI and active TB were also collected as
described.8,28 In particular, the following characteristics
were considered to be LTBI risk factors: birth or residence
for >6 months in a country with a high prevalence of TB
(>20 cases per 100,000 inhabitants); history of household
TB contact; health care workers in facilities following TB
patients. Risk factors for active TB progression were:
a medically-confirmed history of active TB; chest radio-
graph findings suggestive of previous TB (nodules, fibrotic
scars, calcified granulomas or basal pleural thickening);
being HIV-positive; body weight being 10% less than ideal
body weight; presence of comorbidity (diabetes mellitus,
silicosis, chronic renal failure/hemodialysis, neoplastic or
hematological diseases); prolonged therapy with cortico-
steroids (>4 weeks) or other immunosuppressive therapy;
injection drug use; and previous gastrectomy or jejunoileal
bypass.
LTBI definition and therapy
Individuals who tested positive for either TST or QFT-IT
were classified as LTBI6e8 and offered LTBI treatment. The
preferred treatment regimen used was rifampicin (RIF) plus
isoniazid (INH) for 3 months at the standard dosage.7 TNFi
therapy for those who were not already being treated
with TNFi was initiated at the end of LTBI treatment.ON TB-Gold in-tube testing during LTBI therapy in candidates for
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QFT-IT blood samples were obtained before TST perfor-
mance. The samples were incubated at 37 C, within 2e6 h
of blood collection. QFT-IT was performed according to the
manufacturer’s instructions by a biologist who was blinded
to the subjects’ characteristics and TST results.
QFT-IT was repeated upon completion of LTBI therapy
(T1), and again, in a subgroup, 3e6 months after the end of
therapy (T2).
After blood collection, all participants were injected by
a trained physician with using 5 international units (IU) of
tuberculin (Biocine Test-PPD; Chiron, Siena, Italy) until May
2008. Then, in the remaining subjects we used 2 IU of
tuberculin of PPD RT23 (Staten Serum Institute, Copenha-
gen, Denmark), that was shown to have an equivalent
potency of the previous TST.29 The transverse diameter of
induration was measured in millimeters 72 h later using
the ball pen method. TST induration was interpreted ac-
cording to groups at risk and risk factors for MTB infection
in accordance with published guidelines.2,30
QFT-IT: definition of conversion and reversion and
interpretation of results
QFT-IT reversion
QFT-IT test reversion was arbitrarily defined as a change
from a positive (0.35 IU/ml) to a negative (<0.35 IU/ml)
result.
QFT-IT conversion
QFT-IT test conversion was arbitrarily defined as a change
from a negative (<0.35 IU/ml) to a positive (0.35 IU/ml)
result.
Uncertainty zone
Previous studies reported non-specific variations occurring
during IGRA serial testing, defined as “uncertainty zone”
(IFN-g value in response to MTB antigen between 0.20 and
0.50 IU/ml), and “grey zone” (IFN-g value in response to
MTB antigen between 0.10 and 0.35 IU/ml).31,32 Considering
these reports, we also analyzed our data by using the more
stringent definition of conversion and reversion, as indi-
cated by Pai.31 Results in the uncertainty zone were consid-
ered as ‘uncertain’. A person whose IFN-g result increased
from <0.20 to >0.50 IU/ml on the repeated test was con-
sidered to have had a “conversion”. Likewise, a person
whose QFT-IT result decreased from a value of >0.50 to
<0.20 IU/ml was considered to have had a “reversion”. Re-
sults that fluctuated within the uncertainty zone during
repeated testing were considered ‘doubtful conversions’
or ‘doubtful reversions’.
Statistical analysis
Data was analyzed by GraphPad Prism 4.00 (GraphPad
Software, San Diego, CA, USA) and STATA 11.0 (StataCorp,
College Station, TX, USA). For continuous measures, me-
dian and interquartile ranges (IQR) were calculated. The
significance of the differences between the groups was
determined by using the Wilcoxon test for paired data. Non-Please cite this article in press as: Bartalesi F, et al., Serial QuantiFER
TNFi treatment, J Infect (2012), http://dx.doi.org/10.1016/j.jinf.201parametric tests for paired data were used to compare the
continuous measures of IFN-g at the different time points.
In particular KruskaleWallis test was used to compare
medians at T0-T1, and the Friedman test to compare the
medians at T0-T1-T2. For dichotomous measures, chi
square was used. Differences were considered significant
at p-values 0.05. Univariate and multivariate analysis
were performed to analyze the association with the likeli-
hood of reversion among those who scored positive to
QFT-IT at baseline, and the association with the likelihood
of conversion among those who scored negative to QFT-IT
at baseline.
Results
Studied population
A total of 1490 consecutive subjects with IMID were
evaluated in the outpatient service for LTBI screening.
Indeterminate results to QFT-IT were found in 10 subjects
(0.7%). Due to this low number, no significant associations
with the listed IMID therapies were found, different from
a recent report.33 None of the screened subjects were
found to have active TB (by clinical and radiological evalu-
ations) at the time of screening and after a median follow-
up time of 33 months (IQR 21e45 months). Based on our cri-
teria, 249 subjects were classified as LTBI. Among them,
127 (51.0%) were TSTþ/QFT-ITþ, 93 (37.3%) were TSTþ/
QFT-IT, 28 (11.2%) TST/QFT-ITþ and one was indetermi-
nate (0.4%) (Fig. 1). LTBI therapy was offered to all LTBI
subjects. However, 42 subjects refused or were no longer
candidates for biologic therapy for their IMID condition. In-
determinate results were excluded from further analysis.
We included 206 LTBI subjects who underwent therapy in
the analysis. Among them, 166 were followed up from the
screening time (T0) until completion of treatment (T1), and
92 were followed for an additional 3e6 months (T2) (Fig. 1).
Characteristics of the LTBI population are described in
Table 1. Our population was prevalently male, with a me-
dian age of 57.5 years and a low rate of previous BCG-
vaccination. The most frequent underlying disease was
rheumatoid arthritis and most of the subjects were on
some kind of therapy for the rheumatic condition, with
a limited number of subjects who had already started the
TNFi (16e17.5%). No significant differences between the
two subgroups were found (Table 1).
Evaluation of QFT-IT results over time
QFT-IT changes among the 166 LTBI treated-subjects who
were followed-up until T1 are showed (Table 2). Amongst the
55 who scored QFT-IT-negative at baseline (T0), 10 subjects
(18%) converted, and, amongst the 111 subjects who were
scored QFT-IT-positive at baseline, 27 subjects (24%) re-
verted at T1. Of the 166 subjects evaluated, 92 were further
tested at T2 showing a different and not homogeneous pat-
tern of reversion and conversion (data showed in Table 2).
For further analysis from hereafter we consider the data
reported at T0 and T1 unless differently specified. Using the
“uncertainty zone” definition (Table 3), we identified 26
subjects with a “doubtful score”, 17 at baseline and anON TB-Gold in-tube testing during LTBI therapy in candidates for
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Figure 1 Flow diagram of the studied population. Definition of abbreviations: QFT-IT: QuantiFERON-TB Gold in-tube; TST: tuber-
culin skin test; LTBI: latent tuberculosis infection; T0: time of baseline QFT-IT testing; T1: time of LTBI therapy completion; T2:
time 3e6 months after LTBI therapy completion. x Subjects evaluated with repeated QFT-IT at T0 and T1 or, for the subgroup,
at T0, T1 and T2.
4 F. Bartalesi et al.additional 9 at T1. This definition decreased the proportion
of conversion from 18% to 13%, and reversion from 24% to
17%, while the proportion of subjects with stable results
was similar using both definitions. The frequency of rever-
sions and conversions did not differ significantly with either
criteria (p Z 0.370 and p Z 0.496, respectively with stan-
dard and uncertainty zone definitions).
Factors associated with reversion and conversion
Reversion data
We analyzed the factors that may be associated with the
probability of reversion and conversion of the QFT-IT score.Please cite this article in press as: Bartalesi F, et al., Serial QuantiFER
TNFi treatment, J Infect (2012), http://dx.doi.org/10.1016/j.jinf.201Among the 111 subjects who scored QFT-IT-positive at
enrollment, the likelihood of reversion decreased if age
was between 50 and 60 years compared to subjects younger
than 50 years (p Z 0.029), if TST was larger than 15 mm
with respect to sizes smaller than 5 mm (p Z 0.022), if
QFT-IT value at baseline was between 1.0 and 3.0 IU/ml
(p Z 0.005) or higher than 3.0 IU/ml (p < 0.001) with re-
spect to results lower than 1 IU/ml (Table 4). No association
was found between reversion and (i) IMID therapies (com-
paring by univariate analysis the frequency of this event
among each group of subjects under different immune sup-
pressive regimens to that of the group of the untreated
subjects) (ii) the number of risk factors for TB-infectionON TB-Gold in-tube testing during LTBI therapy in candidates for
2.10.017
Table 1 Characteristics of the LTBI-treated population.
Total LTBI-treated N (%) LTBI T0eT1 N (%) LTBI T0eT1eT2 N (%)
Total 206 (100) 166 (80.6) 92 (44.7)
Female gender 97 (47.1) 80 (48.2) 45 (48.9)
BCG-vaccinated 19 (9.2) 15 (9) 7 (7.6)
Birth/residence in countries with
a high prevalence of TB
21 (10.2) 16 (9.6) 8 (8.7)
Median age (years) IQR 57.5 (20; 47e67) 58 (20; 47e67) 58 (19.5; 47.5e67)
Diagnosis
Rheumatoid arthritis 64 (31.1) 56 (33.7) 31 (33.7)
Psoriasis 53 (25.7) 43 (25.9) 19 (20.7)
Psoriatic arthritis 49 (23.8) 36 (21.7) 25 (27.2)
Ankylosing spondylitis 21 (10.2) 17 (10.2) 7 (7.6)
Othera 19 (9.2) 14 (8.4) 10 (10.9)
Therapy
No therapy (in last 3 months) 54 (26.2) 42 (25.3) 23 (25)
Therapy DMARDs and/or steroids 119 (57.8) 95 (57.2) 53 (57.6)
Therapy including TNFi 33 (16) 29 (17.5) 16 (17.4)
Definition of abbreviations: TNFi: tumor necrosis factor a inhibitors, DMARDs: disease-modifying anti-rheumatic drugs, TB: tuberculosis,
BCG: bacillus CalmetteeGue´rin; IQR: interquartile range.
a Includes undifferentiated spondyloarthropathy, sacroiliitis, ulcerative colitis, Crohn’s disease, polymyalgia rheumatica, vasculitis
(three each); systemic sclerosis (one).
Serial QuantiFERON in LTBI therapy 5or (iii) the number of risk factors for active TB-progression
(data not shown).
Further, we stratified the data based on the IFN-g values
at baselines (Table 5). The majority of the subjects scored
TST-positive, independent of the IFN-g value at baseline. InTable 2 QFT-IT score of the 166 LTBI subjects tested at T0 and
QFT-IT at T0 N QFT-IT at T1 N (%
55 Negative (<0.35 UI/ml) 45 (82) negative
10 (18) positive
111 Positive (0.35 UI/ml) 27 (24) negative
84 (76) positive
Definition of abbreviations: QFT-IT: QuantiFERON-TB Gold in-tube (CF
Table 3 QFT-IT reversion and conversion in 166 LTBI subjects at
interpreting QFT-IT results.
QFT at T0
Standard definitiona
Negative (<0.35 IU/ml) (55 subjects)
Positive (0.35 IU/ml) (111 subjects)
“Uncertainty zone” definitionb
Negative (<0.20 IU/ml) (47 subjects)
Positive (>0.50 IU/ml) (102 subjects)
a No significant difference between the likelihood of reversion and
b No significant difference between the likelihood of reversion and
Please cite this article in press as: Bartalesi F, et al., Serial QuantiFER
TNFi treatment, J Infect (2012), http://dx.doi.org/10.1016/j.jinf.201terms of reversion, we found that amongst the 27 subjects
who reverted, 16 (59%, 39e78) had IFN-g values at base-
lines lower than 1.0 IU/ml and that they represented the
majority (16/29, 55%, CI, 36e74) of those with IFN-g values
at baseline lower than 1.0 IU/ml. To note: although the rateT1, and the 92 LTBI subjects followed at T2.
) QFT-IT 3e6 months after T1 (T2) N (%)
22/23 (96) negative
1/23 (4) positive
1/5 (20) negative
4/5 (80) positive
13/17 (76) negative
4/17 (24) positive
4/47 (9) negative
43/47 (91) positive
P-10, ESAT-6 and TB7.7); LTBI: latent tuberculosis infection.
the end of therapy (T1) using two different cut-off criteria for
QFT at T1
Positive e N (%) Negative e N (%)
10 (18) 45 (82)
84 (76) 27 (24)
6(13) 39 (83)
78 (76) 17 (17)
conversion (OR 0.80, p Z 0.370).
conversion (OR 0.46, p Z 0.496).
ON TB-Gold in-tube testing during LTBI therapy in candidates for
2.10.017
Table 4 Factors associated with the likelihood of reversion among the 111 subjects who scored positive to QFT-IT at baseline.
Number (%) Adjusted OR (95%CI) p-Value
Age
<50 20 (18) 1
50e60 33 (30) 0.17 (0.03e0.83) 0.029
>60 58 (52) 0.30 (0.08e1.16) 0.081
Gender
Male 61 (55) 1
Female 50 (45) 1.82 (0.64e5.18) 0.260
TST classes
<5 mm 21 (19) 1
5e9 mm 7 (6) 0.54 (0.07e4.27) 0.557
10e14 mm 14 (13) 0.40 (0.07e2.24) 0.296
15 mm 69 (62) 0.23 (0.06e0.81) 0.022
QFT-IT classes
0.35e1.0 29 (26) 1
1.01e3 27 (24) 0.14 (0.03e0.54) 0.005
>3 55 (50) 0.10 (0.03e0.35) <0.001
Definition of abbreviations: TST: tuberculin skin test; QFT-IT: QuantiFERON-TB Gold in-tube; OR: odds ratio; CI: confidence intervals.
6 F. Bartalesi et al.was lower (13%, CI, 5e25), we also observed a considerable
number of reversions (7/55) in the group of subjects with
high IFN-g values at baselines (>3.0 IU/ml). When the anal-
ysis was performed considering the more stringent defini-
tion of reversion, the results in these two subgroups of
subjects (baseline IFN-g values <1.0 IU/ml and >3.0 IU/
ml) decreased, with a rate of reversion of 40% (CI, 19e64)
and 11% (CI, 4e22), respectively.
Conversion data
Among the 55 subjects who scored QFT-IT-negative at
enrollment, the likelihood of conversion increased signifi-
cantly (p Z 0.014), with higher QFT-IT values at baseline,
whilst it decreased if the gender was female (p Z 0.019).
Differently however, no significant association was found
with age and TST classes (Table 6). No association was
found between conversion and (i) IMID therapies (compar-
ing by univariate analysis the frequency of this event among
each group of subjects under different immune suppressive
regimens to that of the group of the untreated subjects) (ii)
the number of risk factors for TB-infection or (iii) the num-
ber of risk factors for active TB-progression (data not
shown). Among the 10 conversions observed, 6/10 hadTable 5 Rate of reversion at the end of therapy (T1) by base
positive at baseline (T0), considering two different QFT-IT-positiv
Standard definition “Un
Baseline IFN-g
response (IU/ml)
No. of
subjects
T1 QFT-IT
reversion
N (%, C.I.)
TSTþ at T0
N (%, C.I.)
Bas
res
(IU/
0.35e1.0 29 16 (55, 36e74) 23 (79, 63e92) 0.5
1.01e3.0 27 4 (15, 4e34) 21 (78, 58e91) 1.0
>3 55 7 (13, 5e25) 46 (84, 71e92) >3
Total 111 27 (24, 17e33) 90 (81, 73e88) Tot
Definition of abbreviations: TST: tuberculin skin test; QFT-IT: Qua
intervals.
Please cite this article in press as: Bartalesi F, et al., Serial QuantiFER
TNFi treatment, J Infect (2012), http://dx.doi.org/10.1016/j.jinf.201a baseline QFT-IT characterized by IFN-g value above
0.1 UI/ml including 4 with a value above 0.2 that would
have been scored as “doubtful” based on the “uncertainty
zone” definition (data not shown).
Quantitative data of IFN-g production over time
We evaluated the quantitative IFN-g change over time
among those who scored QFT-IT-positive at enrollment. As
shown in Fig. 2A, amongst the 111 subjects evaluated at T0
and T1, the IFN-g level at baseline was higher (median:
0.98; IQR: 0.1e8.8 IU/ml) than that reported at T1 (me-
dian: 0.7; IQR: 0.03e4.4), although not significant
(p Z 0.20). In the 92 subjects who were also evaluated at
T2 (Fig. 2B), we confirm that the IFN-g level at baseline
was higher (median: 1.4; IQR: 0.19e10.0 IU/ml) although
not significantly different than that reported at T1 (me-
dian: 1.01; IQR: 0.01e10.0 IU/ml) (pZ 0.15). However, in-
terestingly, the IFN-g level was significantly higher at
baseline (median: 0.6; IQR: 0.01e4.7 IU/ml) than at T2
(p Z 0.001). Moreover, a significant difference was found
between the IFN-g levels at T1 and those at T2
(p Z 0.004). When the values were analyzed consideringline IFN-g value among the 111 subjects who scored QFT-IT-
e scoring definitions.
certainty zone” definition
eline IFN-g
ponse
ml)
No. of
subjects
T1 QFT-IT
(IFN-g >0.50 UI/ml)
N (%, C.I.)
T1 QFT-IT
“true” reversion
N (%, C.I.)
e1.0 20 8 (40, 19e64) 8 (40, 19e64)
1e3.0 27 22 (81, 62e94) 3 (11, 2e29)
55 48 (87, 76e95) 6 (11, 4e22)
al 102 78 (76, 67e84) 17 (17, 10e25)
ntiFERON-TB Gold in-tube; IFN: interferon; CI: 95% confidence
ON TB-Gold in-tube testing during LTBI therapy in candidates for
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Table 6 Factors associated with the likelihood of conversion among the 55 subjects who scored negative to QFT-IT at baseline.
Number (%) Adjusted OR p-Value
Age
<50 29 (53) 1
50e60 15 (27) 0.40 (0.04e3.86) 0.427
>60 11 (20) 3.56 (0.41e30.6) 0.248
Gender
Male 25 (45) 1
Female 30 (55) 0.06 (0.01e0.63) 0.019
TST classes
5e9 mm 9 (16) 1
10e14 mm 9 (16) 0.92 (0.06e14.2) 0.951
15 mm 37 (67) 0.84 (0.09e7.73) 0.875
QFT-IT
UI/ml at T0 55 (100) 1.10 (1.02e1.19) 0.014
Definition of abbreviations: TST: tuberculin skin test; QFT-IT: QuantiFERON-TB Gold in-tube; OR: odds ratio; CI: confidence intervals.
Figure 2 AeB. Longitudinal analysis of IFN-g secretion in re-
sponse to QFT-IT in the 111 subjects with LTBI with positive
QFT-IT at T0, who were followed until T1 (A) and in the 92 sub-
jects who were also evaluated at T2 (B). Definition of abbrevi-
ations: T0: start of therapy; T1: end of therapy; T2: 3e6
months after LTBI therapy completion; LTBI: latent tuberculo-
sis infection; IMID: immune-mediated inflammatory diseases;
IFN: interferon.
Serial QuantiFERON in LTBI therapy 7all the data simultaneously, a significant difference was
found among the results obtained at the different time
points (Friedman test p Z 0.002).
Discussion
In recent years, a number of studies have been conducted
to investigate the modulation of IFN-g specific response
during LTBI therapy, as measured by IGRAs. These studies
were mainly carried out in health care workers or recent TB
contacts and led to conflicting results, likely due to several
confounding factors, including differences in LTBI treat-
ment protocols, population of subjects studied (health care
workers, recent close TB contacts, recent immigrants),
settings in which repeated exposure to active TB during
LTBI treatment could have occurred (eg, study conducted in
India), and the TB endemic country where the study was
performed (Western countries compared to Asian countries)
(Table 7).17e26
To the best of our knowledge, this is the largest study
(subjects were obtained after screening 1490 IMID patients
who were candidates for TNFi treatment) aimed at evalu-
ating the modulation of IFN-g response during LTBI therapy.
Among the 166 subjects followed up until T1, we observed
a QFT-IT reversion rate of 24% and a conversion rate of 18%;
using more stringent criteria,31 17% reverted and 13%
converted.
Reversion of the IGRA scores after LTBI treatment was
observed in several studies. In the largest cohort described
so far by Chee et al., among 226 treated close contacts, the
score of 38% reverted using the manufacturer’s criteria for
T-SPOT.TB assay.20 More recently, in another cohort of 74
QFT-IT-positive TB contacts, Lee et al. found a similar
rate of reversion (42%).24 Although the results of these
studies are different than ours, there are some similarities.
In our study, the likelihood of achieving a QFT-IT reversion
significantly decreased with older age, larger TST indura-
tion size and higher IFN-g value at baseline QFT-IT. Chee
also reported that CFP-10 reverters were significantly youn-
ger than non-reverters, while no correlation between TST
size and change in CFP-10 responses were observed.20Please cite this article in press as: Bartalesi F, et al., Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for
TNFi treatment, J Infect (2012), http://dx.doi.org/10.1016/j.jinf.2012.10.017
Table 7 IGRA trends in LTBI treated subjects who scored IGRA-positive at baseline.
First author Country IGRA Studied
population
Number of subjects
who scored IGRA-positive
at baseline
LTBI
therapy
Trends
of IGRA
Trends
of IGRA
Reversion at T1 Factors associated with
reversion or decreasing
trendShort term T1 % (95%CI)
Pai, 2006 India QFT-GIT Health care
workers
10 IGRA positive INH
6 months
naa Decreasec 10 (2.5e44.5) naa
Ewer, 2006 UK ELISpot Contacts 38 IGRA positive
25 controls
RIFþINH
3 months
Increase Decrease 8 (1.7e21.4) naa
Wilkinson, 2006 UK ELISpot Immigrants 16 IGRA positive
8 controls
RIFþINH
3 months
Increase Decreasec b naa
Chee, 2007 Singapore T-SPOT.TB Close
contacts
226 IGRA positive INH
6 months
naa Decrease 38 (31.3e44.3) Younger age
Goletti, 2007 Italy QFT-G Contacts 28 IGRA positive
11 controls
INH
6 months
naa Decrease 3.6 (0.1e18.3) No past MTB
exposure
Higuchi, 2008 Japan QFT-G Contacts 28 IGRA positive
5 controls
INH
6 months
naa Decrease 25 (10.7e45) naa
Herrmann, 2009 France QFT-GIT Children
contacts
25 IGRA positive RIFþINH
3 months
Increase Decrease b naa
Lee, 2010 South
Korea
QFT-GIT Contacts 74 IGRA positive RIF
4 months
naa Decrease 42 (30.5e54) Smaller TST size,
lower IFN-g value
Dyrhol-Riise, 2010 Norway QFT-GIT Contacts,
immigrants
and others
40 IGRA positive RIFþINH
3 months
naa No change 12,5 Low IFN-g values at
baseline
Chen, 2012 Taiwan QFT-G RA patients 37 IGRA positive INH
9 months
Decrease Decrease naa Further decline of
IFN-g levels after
TNFi onset
Our data Italy QFT-GIT IMID population 111 IGRA positive RIFþINH
3 months
naa Decrease 24 (16e32) Younger age, smaller
TST size, lower IFN-g
value
Definition of abbreviations: IGRA: interferon-g release assay; QFT-G: QuantiFERON-TB Gold (CFP-10 and ESAT-6); QFT-G IT: QuantiFERON-TB Gold in-tube (CFP-10, ESAT-6 and TB7.7); T1:
end of therapy; IMID: immune-mediated inflammatory diseases; INH: isoniazid; RIF: rifampin; RA: rheumatoid arthritis.
a na Z Not available.
b No percentage of reversion was reported.
c Decreasing trend observed, but not statistically significant.
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Serial QuantiFERON in LTBI therapy 9This result may be due to the fact that TB infection in youn-
ger subjects is more likely to be recently acquired. More-
over, the decline of IFN-g response is more easily and
rapidly achieved after treatment of recent contacts with-
out previous MTB exposure.17 Our results are in agreement
with those reported by Lee, who observed a significantly
larger baseline TST induration size and higher IFN-g levels
among subjects without QFT-IT reversion.24 Similar findings
were reported by Franken et al., in a cohort of TB contacts
in whom a very high IFN-g value (above 4 IU/ml) at baseline
QFT-IT response was associated with the absence of QFT-IT
modulation over a 24-month follow-up period, with or with-
out INH preventive treatment.34
To note: the 12 month reversion after the baseline assay
was also observed in absence of LTBI therapy in 6.4% of
109 TB contacts in an high-burden TB setting (India).31 In
that study, reversion was more likely to occur in those
with QFT-IT results close to the cut-off, while no reversion
was observed in the subgroup that had >3 UI/ml IFN-g
levels at enrollment. In the present report, when we strat-
ified our data by baseline IFN-g values (Table 5), we found
a significantly higher reversion rate among the group with
0.35e1.0 UI/ml IFN-g levels than the group with >3 UI/ml
IFN-g levels (16/29 vs 7/55, p < 0.001), but even in the lat-
ter group the proportion of reversions was noticeable (13%).
The comparison with the Pai et al. study31 is relevant
because it shows two important aspects: first, the assay
per se may have limits of reproducibility or may detect sub-
tle changes that, at present, are difficult to interpret; sec-
ond, it shows the potential impact of LTBI therapy on the
dynamics of IFN-g response, as also suggested by the quan-
titative analysis (see below).
We found that a sizeable proportion of subjects (18%, or
13% if using more stringent criteria) converted at T1. In the
above-mentioned study, Pai et al.,31 using the same defini-
tions, reported a QFT-IT conversion rate of 21.2% and
11.8%, respectively, and suggested that this was probably
due to exposure to MTB that occurred during the follow-
up period. As far as our study is concerned, the low TB en-
demic setting and the shorter follow-up period make it un-
likely that subsequent MTB exposure would contribute to
affecting conversion results. By multivariate analysis, con-
version was significantly associated with higher IFN-g levels
at baseline. In particular, among 10 conversions observed, 6
had IFN-g values above 0.10 UI/ml at baseline including 4
that were above 0.2 and considered “doubtful results”.
Moreover, as previously reported, TST may affect subse-
quent IGRA results in terms of increasing the levels of
IFN-g release appearing from 3 days to some months after
a TST. This effect is more likely in IGRA-positive subjects,
but it has been observed in IGRA-negative individuals
(2e12%).35
In this study, none of the screened subjects, neither
IGRA-score positive, negative or indeterminate subjects,
developed active TB within a 33-month median time of
follow-up observation. This differs from recent reports,26
probably due to the different TB endemic countries (Taiwan
vs Italy) in which the studies were performed.
In summary, it appears unlikely that the observed QFT-IT
variations, at least in qualitative terms, are a real effect of
LTBI treatment in the IMID population studied; they are
probably the effect of the fluctuation of results close to thePlease cite this article in press as: Bartalesi F, et al., Serial QuantiFER
TNFi treatment, J Infect (2012), http://dx.doi.org/10.1016/j.jinf.201cut-off,35 probably due to the limitations of the QFT-IT.36
Moreover it is important to consider that IGRA have a lower
sensitivity in immune-compromised subjects and that the
fluctuations may also reflect the impact of the immune sup-
pressive drugs on the immune system.33,37e39
Based on the available evidence, it is not possible to
define to what extent this variability may be due to host-
biological factors rather than to laboratory or test-related
errors. However, interpreting the reversion or conversion of
IGRAs remains an open issue.35 Probably, assays based on
different antigens and/or biomarkers may be more appro-
priate to evaluate Mb-specific response changes over
time.40e43
We showed that among those who were QFT-IT-positive
at baseline, there was a decrease of IFN-g levels from
baseline to T1, which become highly significant among the
92 subjects followed until T2. This result is in agreement
with that reported in the literature (Table 7), in which an
overall decline of the IFN-g levels after LTBI therapy was
observed, despite the discrepancies in treatment strate-
gies, the IGRAs used, and the country and populations of
subjects studied. Altogether, the quantitative data suggest
that LTBI therapy may reduce IFN-g-specific response,
albeit a control group was not present in most of these
studies, including the present one. However, in the few re-
ports in which a control group was included, no quantitative
changes occurred among the untreated subjects.17,21e23
Taking our and other studies into account, there is
currently no evidence to support the use of QFT-IT in the
clinical practice of monitoring LTBI treatment response. To
further address this issue, larger, longitudinal studies are
needed to evaluate the variation of IGRA scores with the
risk of TB progression.44
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